PATENT CLAIM ANALYSIS

Application Number: 15893771
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-06
Patent Classification: ["514", "415000"]

Abstract:
This invention relates to crystalline forms of (R)-1-(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)indoline-5-carbonitrile, a modulator of the androgen receptor, and methods for the use in treatment.

Claim (Index 3):
The crystalline form of  claim 1  that is further characterized by an  19 F SSNMR spectrum comprising isotropic chemical shifts at \u25a152.7\u00b10.2, \u25a156.0\u00b10.2 and \u25a157.1\u00b10.2 ppm, wherein the  19 F SSNMR spectrum is obtained on a spectrometer operating at a frequency of 470.40 MHz for  19 F observation using a cross-polarization pulse sequence with a Bruker 4-mm triple resonance magic-angle spinning probe at a rotor frequency of 12.5 kHz.

Metadata:
- Claim Count in Document: 34.0
- Percentile: 88.0
- Lexical Diversity: 1.3
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15111068', '13389525', '13941911', '15358458', '14549034']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.727555569797342
- 35 USC 102 Novelty (BERT): 0.5710061460797594
- Combined Prediction Score: 0.7119006274255837
- Mean Citation Score: 238.344134
- Max Citation Score: 441.6624
- Similarity Product: 430.4108549643517

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test